Should I buy Avantor (AVTR) stock or is it too late?

Avantor · Health Care · price $16

⭐ What the most reliable analysts say · those who beat their sector, targets replayed on real prices

⭐ The most reliable of them, either direction: UBS — 64% of its targets hit on this sector (124 calls tested). It aims for $16 (+2.9 %), call made on September 10, 2026, maturing on September 10, 2027 (34 d ago).

The 4 reliable analysts $15.50-0.3 %

The 5 other firms $15-3.5 %

How to read it: the 4 reliable firms are not filtered by optimism — 2 aim above the price, 2 below, hence their $15.50 median. “The 5 others” are the firms that don't pass our reliability filter on this sector.

Firm-by-firm track record on Avantor

Here the hit rate is measured <b>on this stock specifically</b> (matured targets replayed against real prices, minimum 5 calls tested) — the green block above measures reliability <b>across the whole sector</b>, which is the criterion behind JPI selections. “Aims for” = the firm's most recent target on this stock; “—” means it hasn't published one recently.

Firm	% right	Gain vs sector	Calls	Aims for
Citigroup	67 %	+39.7 %	6	$11 -29%
UBS	60 %	+28.4 %	5	$16 +3%
Raymond James	52 %	+7.7 %	21	$16 +3%
Morgan Stanley	44 %	+3.7 %	16	$15 -4%
Goldman Sachs	80 %	-2.2 %	5	$14 -10%
Barclays	38 %	-8.3 %	29	$15 -4%
Wells Fargo	33 %	-9.5 %	12	$16 +3%
Baird	36 %	-12.6 %	14	$17 +9%

In short — Should you invest in Avantor? Is it too late, still worth it? Analysts are split (11% buy, median target $15, i.e. -4%). But it pays virtually no dividend. We give you both sides, with the numbers — not advice.

✅ Reasons to believe

Few solid positives from analysts right now: of 9 ratings, only 1 buys, and the median price target ($15) is -4% below the price ($16). Caution prevails.

⚠️ Reasons to hesitate

Even the most reliable firm on AVTR, Jefferies (100% hit rate, 2 scored calls), only targets $9 (call made on December 17, 2025, maturing on December 17, 2026) (-42%) in its most recent call. The stock may already have run past its target.
The consensus is not unanimous: of 9 ratings, 7 are neutral and 1 is a sell.
Limited upside: the median target is only -4% from the current price.
A 12-month target is not a guaranteed path: the price can fall in the meantime.
No dividend: your return depends only on price appreciation.

The analyst consensus on AVTR

Median target $15 (-4%) · 9 ratings · Hold consensus

Strong Buy00%

Buy111%

Hold778%

Sell111%

Strong Sell00%

⚠️ Information, not investment advice. Past performance does not guarantee future results. Analyst targets on a ~12-month horizon.

Frequently asked questions

Should you invest in Avantor now?

We won't decide for you. The facts: 11% of analysts rate it a buy, median target $15 (-4%), and Jefferies (most reliable on AVTR, 100%) targets $9. Weigh that against valuation. This is not personalized advice.

Is it too late to invest in Avantor?

The stated upside is small: the median target ($15) sits just -4% from the price ($16) (most reliable on AVTR: Jefferies, 100%). The real question isn't "too late" but the price-to-value gap and risk. Not advice.

Is Avantor still worth investing in?

It depends on the gap between the price ($16) and its estimated value: analysts target $15 on median (-4%), with 11% buys (most reliable on AVTR: Jefferies, 100%). Cross-check with their real reliability on AVTR and the cautions above. Information, not advice.

What's the main risk in buying AVTR?

Even the most reliable firm on AVTR, Jefferies (100% hit rate, 2 scored calls), only targets $9 (call made on December 17, 2025, maturing on December 17, 2026) (-42%) in its most recent call. The stock may already have run past its target.

→ Go deeper: the full Avantor profile (consensus, analyst reliability, price target, performance).